http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0970378-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d9647f41b85d79320d26eb6ae4b44bbf |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57473 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57484 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate | 1998-03-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_59c143d2b3ceabd7baae20f49ac23a1b |
| publicationDate | 2000-01-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-0970378-A2 |
| titleOfInvention | $i(IN VITRO) METHOD FOR PROGNOSIS OF THE ILLNESS EVOLUTION OF PATIENTS WITH CARCINOMA OF THE BREAST AND/OR FOR DIAGNOSING CARCINOMA OF THE BREAST |
| abstract | Especially nodal conditions and tumour size, histological type, degree of differentiation and receptor condition are used nowadays for the prognosis and further planning of patients with carcinoma of the breast. Emphasis is placed on evaluation of the condition of the axillary lymph node. Patients with a negative axillary lymph node condition generally receive no after-treatment, as their prognosis is better; yet 30 % of these patients suffer relapses. The method proposed by this invention should make it possible to determine the patient's risk of recividation. In accordance with the invention, the invention makes it possible to predict the further evolution of patients with carcinoma of the breast by means of a qualitative or quantitative determinatin of T1 protein and/or T1-mRNA is sample material taken from the patients. |
| priorityDate | 1997-03-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 298.